NSEGeneral Updates4 Jul 2026 · 4 Jul 2026, 10:34 am

General Updates

Supriya Lifescience Limited · SUPRIYA

✦ AI Summary▼ NegativeRegulatory

Supriya Lifescience Limited has informed the Exchange about General Updates regarding judicial proceedings involving a Personnel of the Company. The investigation has been initiated against Mr. Sreekant Sreedharan, General Manager, Sales & Marketing officer of the Company by Special Investigation and Intelligence branch of Customs Department, subsequent to which judicial custody has been granted by CMM court till July 17, 2026. The Company remains committed to maintaining the highest standards of corporate governance and regulatory compliance.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern8/10
Regulatory Risk9/10
Balance Sheet Risk3/10
Liquidity Impact6/10
Market Sentiment4/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Supriya Lifescience Limited has informed the Exchange about General Updates

Attachments (1)

📄

SUPRIYA_04072026103417_SEIntimation040726.pdf

pdf

Download →
View document text
July 04, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex Mumbai- 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543434 NSE Symbol: SUPRIYA Dear Sir/Madam, Subject: Intimation regarding judicial proceedings involving a Personnel of the Company Pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws, and in accordance with the Regulation 30 read with Para B of Part A of Schedule III of the Listing Regulations and SEBI circular dated July 13, 2023 SEBI Listing Regulations, this is to inform you that the investigation has been initiated yesterday against Mr. Sreekant Sreedharan, General Manager, Sales & Marketing officer of the Company by Special Investigation and Intelligence branch of Customs Department, subsequent to which judicial custody has been granted by CMM court till July 17, 2026. The Company remains committed to maintaining the highest standards of corporate governance and regulatory compliance. The Company is closely monitoring the developments in the case and any further material developments in the matter shall be disclosed to the stock exchanges in accordance with applicable laws and regulations. The details of the case as required under Circular no SEBI/HO/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are enclosed herewith as Annexure A to the disclosure. Kindly take the above information on record. Thanking you. Yours faithfully, For Supriya Lifescience Limited Prachi Sathe Company Secretary & Compliance Officer Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com GOVT. RECOGNISED EXPORT HOUSE Annexure - A Sr. Particulars Details 1. Name Sreekant Sreedharan 2. Designation General Manager, Sales & Marketing 3. Name of the Authority/ Competent Court Special Investigation and Intelligence branch of Customs Department 4. Date of occurrence of the event July 3, 2026 5. Details of the violation(s)/contravention(s) committed or Proceedings have been initiated alleged to be committed against the personnel of the Company yesterday under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985 for a procedural lapse for a single export transaction of identified product for which the said officer is under Judicial detention. 6. Impact on financial, operation or other activities of the Based on information currently listed entity, quantifiable in monetary terms to the available with the Company, the extent possible. proceedings are not expected to have any material impact on the operations, financial position, or governance of the Company 7. Action(s) taken by listed company with respect to the The Company is evaluating the communication implications of the proceedings and is obtaining appropriate legal advice. 8. Any other relevant information The matter is before the competent court, and the Company will take an appropriate action after examining all applicable legal provisions and implications." Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com GOVT. RECOGNISED EXPORT HOUSE